The powder of tetracaine (free base) is a white to off-white crystalline solid, representing the prototype form of ester-based local anesthetics. Its molecular structure is based on p-aminobenzoic acid ester and has strong lipophilicity, enabling it to efficiently penetrate the myelin sheath and cell membranes. Its mechanism of action lies in reversibly blocking the voltage-gated sodium ion channels of neurons, stabilizing the cell membrane, and thereby inhibiting the generation and conduction of nerve impulses. This form of tetracaine is more alkaline and has extremely low water solubility. It usually needs to be dissolved in an acidic solution (such as hydrochloric acid) to form a soluble salt before it can be used for preparing injections or external solutions. As a powerful anesthetic, its toxicity is also significantly higher than procaine. During use, the dosage must be precisely controlled to prevent accidental entry into blood vessels, which could lead to severe systemic toxic reactions such as central nervous system excitation, convulsions, and cardiovascular depression.
|
|
|
|
|
|
|
|
Chemical Properties and Stability Foundation
Molecular Structure and Physical Characteristics
The chemical name of Tetracaine is 4-(butylamino)-benzoic acid-2-(dimethylamino)ethyl ester. Its molecular formula is C₁₅H₂₄N₂O₂, with a molecular weight of 264.36. The powder form of Tetracaine is white crystals or crystalline powder, odorless, slightly bitter in taste, and has a numb sensation. This substance is stable at room temperature, but it needs to be protected from high temperatures, humidity, and light. Its melting point is 41-45℃, the boiling point is approximately 389.4℃, the density is 1.044 g/cm³, and the refractive index is 1.537. These physical parameters indicate that tetracaine can remain stable under normal storage conditions (such as sealed and in a cool, dry place) for a long time, but high temperatures may lead to decomposition or volatilization, and strict control of storage temperature is required.
Solubility and Chemical Stability
Tetracaine is readily soluble in water and alcohols (such as methanol and ethanol), but has a relatively low solubility in non-polar solvents (such as ether and benzene). Its water solubility is 156 mg/L (the temperature is not specified), indicating a moderate solubility in water, which is convenient for formulation preparation. In terms of chemical stability, tetracaine is stable in a dry environment, but may accelerate oxidation or hydrolysis reactions upon moisture absorption. For example, its hydrochloride form (molecular formula C₁₅H₂₅ClN₂O₂, molecular weight 300.82) may absorb moisture and form lumps in a humid environment, affecting the usage effect. Therefore, it should be stored sealed and avoided to be mixed with food raw materials to prevent cross-contamination.
Storage Conditions and Stability Management
The storage conditions of Tetracaine powder directly affect its stability. The recommended storage temperature is 2-8℃. If long-term storage is required (such as more than 6 months), it is recommended to store it at a temperature below -20℃ to slow down the decomposition rate. The storage container must be sealed to prevent mixing with oxidants, halogens, halides, etc., which could cause violent reactions. Additionally, Tetracaine powder is sensitive to light, and it needs to be stored in a dark place to prevent photolysis reactions that could lead to degradation of the active ingredients. Regularly checking the storage environment (such as temperature and humidity) and the sealing of the container are key measures to ensure its stability.
Safety: From Pharmacological Effects to Toxicity Risks
Pharmacological Effects and Clinical Applications
Tetracaine is a potent local anesthetic that blocks voltage-dependent sodium channels on nerve cell membranes, inhibiting sodium ion influx, thereby blocking the conduction of nerve impulses and producing anesthetic effects. Its local anesthetic effect is 10 times stronger than procaine, but it is also more toxic (about 10-20 times higher). Tetracaine is mainly used for surface anesthesia of the eyes, nose, throat, and urinary tract, such as corneal anesthesia in ophthalmic surgeries and endoscopy in otolaryngology. Its hydrochloride salt formulation (such as hydrochloric tetracaine injection) is a colorless clear liquid, with a common concentration of 0.1% - 2%. The single dose limit varies depending on the purpose (such as 40 mg for mucosal surface anesthesia and 100 mg for the maximum limit of nerve conduction block).
Toxicity reactions and poisoning mechanism
The toxicity of tetracaine mainly stems from its potent sodium channel-blocking effect. Excessive use or accidental injection into blood vessels can lead to excessively high blood drug concentration, causing central nervous system excitation (such as dizziness, vertigo, chills, tremors, panic), hypotension and cardiac inhibition (such as respiratory failure, blood pressure drop), and in severe cases, convulsions and coma. The acute toxicity data of tetracaine (such as the LD₅₀ for rats via intravenous injection being 6 mg/kg and for mice via intraperitoneal injection being 20 mg/kg) indicate that tetracaine is a highly toxic substance, and the dosage and operational procedures must be strictly controlled. Additionally, tetracaine may trigger allergic reactions (such as rashes, urticaria, facial or oral-throat edema), and even cause sudden death in allergic patients. Even during surface anesthesia, caution is necessary.
Special Populations and Usage Restrictions
The use of tetracaine in special populations should be cautious. Elderly patients, due to decreased liver and kidney function and reduced metabolic capacity, should use it at a reduced dose; children under 5 years old, due to their lighter weight and incompletely developed metabolic systems, should use it with caution; pregnant and lactating women need to adjust the dosage to avoid any impact on the fetus or infant. Additionally, tetracaine is prohibited for those who are allergic to the drug, those with severe liver or kidney dysfunction, and patients with severe shock. In ophthalmic surgeries, tetracaine solution should be avoided from directly contacting the cornea to prevent corneal epithelial damage.
Operating Procedures and Emergency Response
1. Personal Protective Equipment (PPE)
When handling tetracaine powder, it is necessary to wear a protective mask, chemical safety goggles, chemical-resistant gloves (such as nitrile rubber), and laboratory coat to prevent direct skin contact or inhalation of dust. Operate in a fume hood or local exhaust system to ensure air circulation and reduce the concentration of tetracaine in the air. After the operation, thoroughly clean the skin and clothing to avoid irritation to the skin or mucous membranes from residual substances.
2. Emergency Handling of Leakage
In case of a carbocaine powder leakage, immediately isolate the contaminated area, restrict access, and cut off the source of fire. For small leaks, cover with damp sand or soil and collect in a dry, clean, and covered container; for large leaks, wet with water and collect and recover using spark-free tools or transport to a waste disposal site for disposal. During the leakage handling process, wear protective equipment to avoid direct contact with the leakage material.
3. Emergency Treatment for Poisoning
The emergency treatment for tetracaine poisoning should be carried out based on the route of poisoning and symptoms, and specific measures should be taken accordingly:
Skin contact: Remove contaminated clothing and thoroughly rinse the skin with soapy water and clean water.
Eye contact: Raise the eyelids and rinse with flowing water or physiological saline for at least 15 minutes. If wearing contact lenses and they can be easily removed, remove the contact lenses and continue rinsing.
Inhalation: Quickly leave the scene to a fresh air area, keep the airway clear. If breathing difficulties occur, administer oxygen. If breathing stops, perform artificial respiration immediately.
Ingestion: Drink plenty of warm water, induce vomiting, do not give anything to the unconscious person through the mouth, and seek medical attention immediately.
Regulations and Compliance Requirements
Drug Classification and Regulation
Tetracaine is a prescription drug (℞-only). In Australia, it is classified as S4 (requiring a prescription) and S2 (requires pharmacist guidance for pharmacy sales), in Brazil it is classified as C1 (other controlled substances), and in the United States, it must be used with a prescription. Its production, storage, and transportation must comply with the Good Manufacturing Practice for Pharmaceuticals (GMP) and the regulations for dangerous goods transportation (such as UN 2811).
Waste disposal and environmental protection requirements
The discarded Tetracaine should be handled by an institution with qualifications for hazardous waste disposal to prevent ecological pollution. The data on its biodegradability is limited, but it is speculated that its degradation rate in the natural environment is relatively slow, so it needs to be managed with caution. During the waste disposal process, the "Management Measures for Hazardous Waste Transfer Forms" must be followed to ensure that the entire process of the waste is traceable.
Labeling and Packaging Requirements
The packaging of Tetracaine powder should include information such as the drug name, specification, batch number, production date, expiration date, storage conditions, and warning signs (such as "poisonous" or "flammable"). The labels must be clear and complete for easy identification and management. During storage, it is necessary to regularly check whether the packaging is intact and sealed to prevent moisture or deterioration.